Beyond tyrosine kinase inhibitors: Combinations and other agents

Area of Science:

• Hematology
• Oncology
• Stem Cell Biology

Background:

• Tyrosine kinase inhibitors (TKIs) have revolutionized chronic myeloid leukemia (CML) treatment, achieving high molecular response rates.
• Despite TKI efficacy, minimal residual disease (MRD) persists in most CML patients, indicating the presence of leukemia stem cells (LSCs).
• Eliminating CML LSCs is crucial for achieving a definitive cure and preventing relapse.

Purpose of the Study:

• To review current and emerging therapeutic strategies aimed at eradicating CML stem cells.
• To highlight the clinical relevance of targeting LSCs in CML management.
• To discuss ongoing research into novel agents and immunotherapies for CML.

Main Methods:

• Review of current literature on CML therapeutics.
• Analysis of ongoing clinical trials for novel CML stem cell targeting agents.
• Evaluation of immunological approaches, including vaccination and combination therapies.

Main Results:

• First and second-generation TKIs have significantly improved CML patient outcomes.
• Minimal residual disease remains a challenge, underscoring the need for LSC-targeting therapies.
• Several novel agents and combination strategies are under investigation in early-phase clinical trials.

Conclusions:

• Targeting CML stem cells holds significant clinical promise for improving cure rates.
• Immunological approaches and combination therapies represent promising avenues for LSC eradication.
• Continued research and clinical trials are essential to develop effective strategies against CML stem cells.